膝下股腘动脉搭桥:肝素涂层聚四氟乙烯与自体静脉远期结局比较
结论认为静脉仍是首选移植材料。
要点
- 膝下股腘动脉搭桥在CLI不适合腔内治疗患者中结果良好。
- 5年一期和二期通畅率静脉与HePTFE无显著差异。
- 静脉组5年保肢率显著优于HePTFE组(90.0% vs 62.9%)。
核心结论
- 对于不适合腔内治疗的CLI患者,膝下股腘动脉搭桥结果良好,静脉仍是首选移植材料。
研究设计与样本
- 共纳入151例,静脉组76例,肝素涂层膨胀聚四氟乙烯(HePTFE)组75例。
临床怎么用
- 在CLI且不适合腔内治疗的患者中,膝下股腘动脉搭桥可考虑,静脉应作为首选移植物。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Endovascular first is the preferred therapy approach to critical limb ischaemia (CLI). However, in spite of new endovascular techniques, bypass surgery still plays an important role, especially in patients with complex anatomy in whom endovascular therapy is not considered feasible, or has failed. The goal of this study was to analyse the outcomes of prosthetic or autologous vein for femoropopliteal (P3) bypasses performed under the abovementioned conditions. METHODS: A retrospective analysis of patients who underwent a femoropopliteal (P3) bypass for CLI (March 2007-December 2015) was conducted. Endovascular therapy was not possible. Patency rates, limb salvage, major adverse limb event (MALE) free survival, and survival after 5 years were analysed. RESULTS: In total, 151 cases were included in the analysis (rest pain 35.8%, ulcer/gangrene 64.3%). The graft material was autologous vein in 76 cases (vein group) and heparin bonded expanded polytetrafluoroethylene (HePTFE) in 75 cases (HePTFE group). Indications, risk factors, previous revascularisation procedures, and runoff vessels were similar in both groups. Thirty day mortality was 6.6% in the vein group and 5.3% in the HePTFE group (p = .508), early graft occlusion (6.6% vs. 5.3%; p = .508) and 30 day major amputation rate (0% vs. 2.7%; p = .245) were similar between the two groups. Overall primary patency was 51.7% (55.5% [vein group] vs. 51.7% [HePTFE group]; p = .897) and overall secondary patency was 64.2% (74.6% [vein group] vs. 55.6% [HePTFE group]; p = .119), all without significance after 5 years. However, limb salvage (79.1%) was significantly different (90.0% [vein group] vs. 62.9% [HePTFE group]; p = .021). Survival was similar between the groups (47.3% vs. 42.9%; p = .582) as well as MALE free survival (69.4% vs. 55.0%; p = .348). CONCLUSION: Bypasses to the below knee popliteal artery show good results in patients with CLI unsuitable for endovascular therapy. Vein is still the first line graft material.
引用
- Uhl C, Grosch C, Hock C, et al. Comparison of Long-term Outcomes of Heparin Bonded Polytetrafluoroethylene and Autologous Vein Below Knee Femoropopliteal Bypasses in Patients with Critical Limb Ischaemia. Eur J Vasc Endovasc Surg. 2017. PMID: 28587797. doi:10.1016/j.ejvs.2017.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。